FrancophonIA/ELRC3.0 huggingface dataset:
English: • a delay in menstrual periods, breast enlargement
Norwegian Bokmål: • forsinket menstruasjon, brystforstørrelse
English: Hepatobiliary disorders transaminases increased gamma-glutamyltran sferase increased, hepatic enzyme increased jaundice
Norwegian Bokmål: Sykdommer i lever og galleveier økte transaminaser økt gammaglutamyltransferase, økte leverenzymer gulsott
English: Vascular disorders orthostatic hypotension, hypertension hypotension pulmonary embolism, venous thrombosis,
Norwegian Bokmål: Karsykdommer ortostatisk hypotensjon, hypertensjon hypotensjon lungeemboli, venetrombose, iskemi, rødming
English: The adverse drug reactions (ADRs) most frequently reported in clinical trials with adults were headache, insomnia, sedation/somnolence, parkinsonism, akathisia, tachycardia, tremor, dystonia, upper respiratory tract infection, anxiety, dizziness, weight increased, nausea, agitation, constipation, vomiting, fatigue, depression, dyspepsia, diarrhoea, dry mouth, toothache, musculoskeletal pain, hypertension, asthenia, back pain, electrocardiogram QT prolonged, and cough.
Norwegian Bokmål: Bivirkningene som ble hyppigst rapportert i kliniske studier med voksne var hodepine, søvnløshet, sløvhet/søvnighet, parkinsonisme, akatisi, takykardi, tremor, dystoni, øvre luftveisinfeksjon, angst, svimmelhet, vektøkning, kvalme, agitasjon, forstoppelse, oppkast, fatigue, depresjon, dyspepsi, diaré, munntørrhet, tannpine, smerter i muskler og skjelett, hypertensjon, asteni, ryggsmerter, QT-forlengelse i elektrokardiogram og hoste.
English: The recommended starting dose for treating schizophrenia in adolescents 15 years and older is 3 mg once a day taken in the morning.
Norwegian Bokmål: Den anbefalte startdosen for behandling av schizofreni hos ungdom 15 år eller eldre er 3 mg én gang daglig, tatt om morgenen.
English: 14 prolonged-release tablets 28 prolonged-release tablets 49 prolonged-release tablets 56 prolonged-release tablets 98 prolonged-release tablets
Norwegian Bokmål: 14 depottabletter 28 depottabletter 49 depottabletter 56 depottabletter 98 depottabletter
English: When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 5 days.
Norwegian Bokmål: Når doseøkning er indisert anbefales økning á 3 mg/dag, og dette bør normalt foretas i intervaller på mer enn 5 dager.
English: Schizophrenia Studies: Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score - Change From Baseline to End Point - LOCF for Studies R076477-SCH-303, R076477-SCH-304, and R076477-SCH-305: Intent-to-Treat Analysis Set
Norwegian Bokmål: Schizofrenistudier: Totalscore på PANSS (Positiv and Negativ Syndrome Scale) for Schizofreni (PANSS)endring fra utgangsverdien til endepunktet - LOCF for studiene R076477-SCH-303, R076477-SCH-304 og R076477-SCH-305: Intent-to-Treat analysesett
English: Hydroxyethyl Cellulose Polyethylene glycol 3350
Norwegian Bokmål: Polyetylenglykol 3350
English: Hypersensitivity to the active substance, risperidone, or to any of the excipients listed in section 6.1.
Norwegian Bokmål: Overfølsomhet overfor virkestoffet, risperidon, eller overfor et eller flere av hjelpestoffene listet opp i pkt.
English: If you stop INVEGA
Norwegian Bokmål: Dersom du avbryter behandling med INVEGA
English: Skin and subcutaneous tissue disorders pruritus, rash urticaria, alopecia, eczema, acne angioedema, drug eruption c, hyperkeratosis, dry skin, erythema, skin discolouration, seborrhoeic dermatitis, dandruff
Norwegian Bokmål: Hud og underhudssykdommer kløe, utslett urticaria, alopeci, eksem, akne angioødem, legemiddelutslett c, hyperkeratose, tørr hud, erytem, hudmisfarging, seboreisk eksem, flass
English: 14 prolonged-release tablets 28 prolonged-release tablets 30 prolonged-release tablets 49 prolonged-release tablets 56 prolonged-release tablets 98 prolonged-release tablets
Norwegian Bokmål: 14 depottabletter 28 depottabletter 30 depottabletter 49 depottabletter 56 depottabletter 98 depottabletter
English: Schizophrenia Studies: Proportion of Subjects with Responder Status at LOCF End Point Studies R076477-SCH-303, R076477-SCH-304, and R076477-SCH-305: Intent-to-Treat Analysis Set
Norwegian Bokmål: Schizofrenistudier: Andel av forsøkspersoner med responderstatus ved LOCF endepunkt Studie R076477-SCH-303, R076477-SCH-304 og R076477-SCH-305: Intent-to-Treat analysesett
English: • a blockage in the bowels, stool incontinence, very hard stool, lack of bowel muscle movement that causes blockage
Norwegian Bokmål: • tarmobstruksjon, avføringsinkontinens, svært hard avføring, manglende tarmtømming som gir forstoppelse
English: disturbance in attention, dysarthria, dysgeusia, hypoaesthesia, paresthaesia neuroleptic malignant syndrome, cerebral ischaemia, unresponsive to stimuli c, loss of consciousness, depressed level of consciousness c,
Norwegian Bokmål: tremor tardiv dyskinesi, kramper e, synkope, psykomotorisk hyperaktivitet, postural svimmelhet, oppmerksomhetsforstyrrelse, dysartri, dysgeusi,hypestesi, parestesi nevroleptisk malignt syndrom, cerebral iskemi, manglende respons på stimuli c, tap av bevissthet, redusert bevissthetsnivå c,
English: Paliperidone
Norwegian Bokmål: Depottablett
English: Mean baseline (SD) Mean change (SD) P-value (vs, Placebo) Diff. of LS Means (SE)
Norwegian Bokmål: Gjennomsnittlig endring (SD) P-verdi (vs. Placebo) Diff. av LS gj.snitt (SE)
English: • sore throat, cough, stuffy nose
Norwegian Bokmål: • sår hals, hoste, tett nese
English: How to store INVEGA
Norwegian Bokmål: Hvordan du oppbevarer INVEGA
English: If you take more INVEGA than you should
Norwegian Bokmål: Dersom du tar for mye av INVEGA
English: Because of its potential for inducing orthostatic hypotension (see section 4.4), an additive effect may be observed when INVEGA is administered with other therapeutic agents that have this potential, e.g., other antipsychotics, tricyclics.
Norwegian Bokmål: 4.4) kan en additiv effekt sees når INVEGA gis samtidig med andre terapeutiske midler med samme potensiale, f.eks. andre antipsykotika, trisykliske antidepressiva.
English: • shortness of breath, wheezing, nosebleeds
Norwegian Bokmål: • kortpustethet, hvesing, neseblødning
English: • infection of the chest (bronchitis), common cold symptoms, sinus infection, urinary tract infection, feeling like you have the flu
Norwegian Bokmål: • infeksjon i brystet (bronkitt), forkjølelsessymptomer, bihulebetennelse, urinveisinfeksjon,
English: Change in PANSS Score 8 week, acute endpoint Mean baseline (SD) Mean change (SD) P-value (vs aripiprazole) Diff. of LS Means (SE)
Norwegian Bokmål: Endring i PANSS-score Gjennomsnittlig baseline (SD) Gjennomsnittlig endring (SD) P-verdi (vs. placebo) Diff. av LS gj.snitt (SE)
English: The recommended dose of INVEGA for the treatment of schizoaffective disorder in adults is 6 mg once daily, administered in the morning.
Norwegian Bokmål: Anbefalt dose av INVEGA for behandling av schizoaffektiv lidelse hos voksne er 6 mg én gang daglig, gitt om morgenen.
English: confusional state, libido decreased, anorgasmia, nervousness, nightmare catatonia, somnambulism, blunted affect
Norwegian Bokmål: Psykiatriske lidelser søvnløshet e mani, agitasjon, depresjon, angst søvnlidelse, forvirringstilstand, redusert libido, anorgasmi, nervøsitet, mareritt katatoni, somnambulisme, avstumpet affekt
English: Based on in vitro studies utilising human liver enzymes, paliperidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of paliperidone.
Norwegian Bokmål: I følge in vitro-studier med humane leverenzymer er ikke paliperidon et substrat for CYP1A2.
English: • stomach pain
Norwegian Bokmål: • tette lunger
English: • development of breasts in men, enlargement of the glands in your breasts, discharge from the breasts, vaginal discharge
Norwegian Bokmål: • brystutvikling hos menn, forstørrelse av brystkjertlene, sekresjon av væske fra brystene, utflod fra skjeden
English: INVEGA is for oral administration.
Norwegian Bokmål: INVEGA gis oralt.
English: Ferric oxide (red) (E172) Carnauba wax
Norwegian Bokmål: Jernoksid (rødt) (E172) Karnaubavoks
English: INVEGA 3 mg prolonged-release tablets INVEGA 6 mg prolonged-release tablets INVEGA 9 mg prolonged-release tablets INVEGA 12 mg prolonged-release tablets paliperidone
Norwegian Bokmål: INVEGA 3 mg depottabletter INVEGA 6 mg depottabletter INVEGA 9 mg depottabletter INVEGA 12 mg depottabletter paliperidon
English: The safety and efficacy of INVEGA in the treatment of schizophrenia in adolescents between 12 and 14 years old has not been established.
Norwegian Bokmål: Sikkerhet og effekt av INVEGA hos ungdom i alderen 12 til 14 år har ikke blitt fastslått.
English: • lung congestion
Norwegian Bokmål: • vektøkning
English: Schizoaffective Disorder Studies: Secondary Efficacy Parameter, Proportion of Subjects with Responder Status at LOCF End Point: Studies R076477-SCA-3001 and R076477-SCA-3002: Intent-to-Treat Analysis Set
Norwegian Bokmål: Studier av schizoaffektiv lidelse: Parameter for sekundær effekt, Andel forsøkspersoner med responderstatus ved LOCF endepunkt: Studiene R076477-SCA-3001 og R076477-SCA-3002: Intent-to-Treat analysesett
English: The recommended dose of INVEGA for the treatment of schizophrenia in adults is 6 mg once daily, administered in the morning.
Norwegian Bokmål: Anbefalt dose av INVEGA for behandling av schizofreni hos voksne er 6 mg én gang daglig, gitt om morgenen.
English: In schizophrenia clinical trials, increases in serum prolactin were observed with INVEGA in 67% of subjects.
Norwegian Bokmål: Økning av serumprolaktin ble observert hos 67 % av pasientene som fikk INVEGA i kliniske studier ved schizofreni.
English: In all three studies, INVEGA was superior to placebo on PSP and CGI-S. Efficacy was also evaluated by calculation of treatment response (defined as decrease in PANSS Total Score ≥ 30%) as a secondary endpoint.
Norwegian Bokmål: Effekten ble også vurdert ved beregning av behandlingsrespons (definert som reduksjon i PANSS totalscore ≥ 30 %) som et sekundært endepunkt.\
English: • blurry vision
Norwegian Bokmål: • endret ganglag
English: Paliperidone is excreted in the breast milk to such an extent that effects on the breast-fed infant are likely if therapeutic doses are administered to breast-feeding women.
Norwegian Bokmål: Når en ammende mor får terapeutiske doser paliperidon, vil paliperidon utskilles i brystmelk i en slik grad at det diende barnet sannsynligvis påvirkes.
English: ejaculation disorder, menstrual disorder e, galactorrhoea, sexual dysfunction, breast pain, breast discomfort priapism c, menstruation delayed gynaecomastia, breast engorgement,
Norwegian Bokmål: Lidelser i kjønnsorganer og brystsykdommer amenoré erektil dysfunksjon, ejakulasjonsforstyrrelse, menstruasjonsforstyrrelse e, galaktoré, seksualforstyrrelse, smerter i brystene, ubehag i brystene priapisme c,
English: BOTTLE
Norwegian Bokmål: FLASKE
English: waist circumference increased, anorexia, blood triglycerides increased water intoxication, diabetic ketoacidosis c, hypoglycaemia, polydipsia, blood cholesterol increased hyperinsulinaemi
Norwegian Bokmål: Stoffskifte- og ernæringsbetingede sykdommer vektøkning, økt appetitt, vekttap, nedsatt appetitt diabetes mellitus d, hyperglykemi, økt midjemål, anoreksi, økte triglyserider i blod vannforgiftning, diabetisk ketoacidose c, hypoglykemi, polydipsi, økt blodkolesterol
English: Musculoskelet al and connective tissue disorders musculoskeletal pain, back pain, arthralgia blood creatine phosphokinase increased, muscle spasms, joint stiffness, joint swelling, muscular weakness, neck pain rhabdomyolysis c, posture abnormal
Norwegian Bokmål: Sykdommer i muskler, bindevev og skjelett smerter i muskler og skjelett, ryggsmerter, artralgi økt kreatinkinase i blod, muskelspasmer, leddstivhet, leddhevelse, muskelsvakhet, nakkesmerter rabdomyolyse c,
English: If you notice any of these symptoms seek medical advice immediately.
Norwegian Bokmål: Oppsøk medisinsk hjelp umiddelbart dersom du opplever noen av disse symptomene.
English: There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of medicines in non-deformable controlled-release formulations.
Norwegian Bokmål: Ikke-formbare depotformuleringer av legemidler har i sjeldne tilfeller ført til obstruktive symptomer hos pasienter med kjente strikturer.
English: Trilayer capsule-shaped white tablets of 11 mm in length and 5 mm in diameter printed with “PAL 3” Trilayer capsule-shaped beige tablets of 11 mm in length and 5 mm in diameter printed with “PAL 6” Trilayer capsule-shaped pink tablets of 11 mm in length and 5 mm in diameter printed with “PAL 9” Trilayer capsule-shaped yellow tablets of 11 mm in length and 5 mm in diameter printed with “PAL 12”
Norwegian Bokmål: Tre-lags, kapselformede, beige tabletter som er 11 mm lange og 5 mm i diameter og merket med ”PAL 6”.
English: Elimination of paliperidone decreased with decreasing renal function.
Norwegian Bokmål: Redusert nyrefunksjon medførte redusert utskillelse av paliperidon.
English: Butyl hydroxytoluene (E321) Ferric Oxide (Yellow) (E172) (3, 12 mg tablet only) Polyethylene Oxide 7000K Ferric Oxide (Red) (E172)
Norwegian Bokmål: Butylhydroksytoluen (E321) Jernoksid (gul) (E172) (kun 3 og 12 mg tabletter) Polyetylenoksid 7000K
English: • swollen tongue, stomach or intestinal infection, difficulty swallowing, excessive passing of gas or wind
Norwegian Bokmål: • hoven tunge, mage- eller tarminfeksjon, svelgevansker, mer luft i magen
English: Each INVEGA 9 mg prolonged-release tablet contains 9 mg of paliperidone.
Norwegian Bokmål: Hver INVEGA 9 mg depottablett inneholder 9 mg paliperidon.
English: In clinical trials with some other atypical antipsychotics, increased risks of death and cerebrovascular accidents have been reported (see section 4.4).
Norwegian Bokmål: Økt risiko for død og cerebrovaskulære hendelser har blitt rapportert i kliniske studier med noen andre atypiske antipsykotika (se pkt.
English: INVEGA 3 mg prolonged-release tablets INVEGA 6 mg prolonged-release tablets INVEGA 9 mg prolonged-release tablets INVEGA 12 mg prolonged-release tablets
Norwegian Bokmål: INVEGA 3 mg depottabletter INVEGA 6 mg depottabletter INVEGA 9 mg depottabletter INVEGA 12 mg depottabletter
English: Iron oxide (Black) (E172) Propylene glycol Hypromellose
Norwegian Bokmål: Jernoksid (sort) (E172) Propylenglykol Hypromellose
English: pollakiuria, urinary retention, dysuria
Norwegian Bokmål: Sykdommer i nyre og urinveier urininkontinens, pollakiuri, urinretensjon, dysuri
English: Oriented polyamide (OPA)-aluminium-polyvinyl chloride (PVC)/aluminium push-through child-resistant blister.
Norwegian Bokmål: Barnesikret blisterpakning av orientert polyamid (OPA)-aluminium-polyvinylklorid (PVC)/gjennomtrykksfolie av aluminium.
English: Each prolonged-release tablet contains 9 mg of paliperidone.
Norwegian Bokmål: Hver depottablett inneholder 9 mg paliperidon.
English: Hypromellose Titanium dioxide (E171) Polyethylene glycol 400 Ferric oxide (red) (E172) Carnauba wax
Norwegian Bokmål: Hypromellose Titandioksid (E171) Polyetylenglykol 400 Jernoksid (gult) (E172) Karnaubavoks
English: The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.
Norwegian Bokmål: Pasienter trenger ikke å bekymre seg hvis de av og til merker noe som ligner på en tablett i avføringen.
English: • pneumonia caused by inhaling food, congestion of breathing passages, voice disorder
Norwegian Bokmål: • lungebetennelse som skyldes at mageinnhold kommer ned i lungene, tette luftveier,
English: Schizoaffective Disorder Studies: Primary Efficacy Parameter, PANSS Total Score Change from Baseline from Studies R076477-SCA-3001 and R076477-SCA-3002: Intent-to-Treat Analysis Set
Norwegian Bokmål: Studier av schizoaffektiv lidelse: Parameter for primær effekt, PANSS totalscoreendring fra studiene R076477-SCA-3001 og R076477-SCA-3002: Intent-to-Treat analysesett Placebo INVEGA Lavere dose (3-6 mg)
English: Seizures
Norwegian Bokmål: Drasjering
English: Each INVEGA 12 mg prolonged-release tablet contains 12 mg of paliperidone.
Norwegian Bokmål: Hver INVEGA 12 mg depottablett inneholder 12 mg paliperidon.
English: Each INVEGA 6 mg prolonged-release tablet contains 6 mg of paliperidone.
Norwegian Bokmål: Hver INVEGA 6 mg depottablett inneholder 6 mg paliperidon.
English: 59% of the dose was excreted unchanged into urine, indicating that paliperidone is not extensively metabolised by the liver.
Norwegian Bokmål: C-paliperidon med umiddelbar frigivelse ble 59 % av dosen utskilt uendret i urin.
English: Each prolonged-release tablet contains 12 mg of paliperidone.
Norwegian Bokmål: Hver depottablett inneholder 12 mg paliperidon.
English: • severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash and sometimes drop in blood pressure, allergic reaction
Norwegian Bokmål: • alvorlig allergisk reaksjon med feber, hevelse i munn, ansikt, lepper eller tunge, kortpustethet,
English: Each INVEGA 3 mg prolonged-release tablet contains 3 mg of paliperidone.
Norwegian Bokmål: Hver INVEGA 3 mg depottablett inneholder 3 mg paliperidon.
English: Printing ink Iron oxide (black) (E172)
Norwegian Bokmål: Jernoksid (rød) (E172)
English: Propylene glycol Hypromellose
Norwegian Bokmål: Hydroksyetylcellulose
English: Each prolonged-release tablet contains 3 mg of paliperidone.
Norwegian Bokmål: Hver depottablett inneholder 3 mg paliperidon.
English: Mean baseline (SD) Mean change (SD) P-value (vs.
Norwegian Bokmål: Gjennomsnittlig baseline (SD)
English: Each prolonged-release tablet contains 6 mg of paliperidone.
Norwegian Bokmål: Hver depottablett inneholder 6 mg paliperidon.
English: 30 prolonged-release tablets - EU/1/07/395/057 350 prolonged-release tablets - EU/1/07/395/058
Norwegian Bokmål: 30 depottabletter - EU/1/07/395/057 350 depottabletter - EU/1/07/395/058
English: • itching, rash
Norwegian Bokmål: • skjelving (risting)
English: 30 prolonged-release tablets - EU/1/07/395/063 350 prolonged-release tablets - EU/1/07/395/064
Norwegian Bokmål: 30 depottabletter - EU/1/07/395/063 350 depottabletter - EU/1/07/395/064
English: 30 prolonged-release tablets - EU/1/07/395/061 350 prolonged-release tablets - EU/1/07/395/062
Norwegian Bokmål: 30 depottabletter - EU/1/07/395/061 350 depottabletter - EU/1/07/395/062
English: 30 prolonged-release tablets - EU/1/07/395/059 350 prolonged-release tablets - EU/1/07/395/060
Norwegian Bokmål: 30 depottabletter - EU/1/07/395/059 350 depottabletter - EU/1/07/395/060
English: 14 prolonged-release tablets - EU/1/07/395/074 - CLEAR 28 prolonged-release tablets - EU/1/07/395/016 - CLEAR 30 prolonged-release tablets - EU/1/07/395/017 - CLEAR 49 prolonged-release tablets - EU/1/07/395/018 - CLEAR 56 prolonged-release tablets - EU/1/07/395/019 - CLEAR 98 prolonged-release tablets - EU/1/07/395/020 - CLEAR
Norwegian Bokmål: 14 depottabletter - EU/1/07/395/074 - KLAR 28 depottabletter - EU/1/07/395/016 - KLAR 30 depottabletter - EU/1/07/395/017 - KLAR 49 depottabletter - EU/1/07/395/018 - KLAR 56 depottabletter - EU/1/07/395/019 - KLAR 98 depottabletter - EU/1/07/395/020 - KLAR
English: EXP MM/YYYY
Norwegian Bokmål: P-verdi (vs. aripiprazol)
English: Hepatic impairment
Norwegian Bokmål: unormal kroppsholdning
English: 14 prolonged-release tablets - EU/1/07/395/071 - CLEAR 28 prolonged-release tablets - EU/1/07/395/011 - CLEAR 30 prolonged-release tablets - EU/1/07/395/012 - CLEAR 49 prolonged-release tablets - EU/1/07/395/013 - CLEAR 56 prolonged-release tablets - EU/1/07/395/014 - CLEAR 98 prolonged-release tablets - EU/1/07/395/015 - CLEAR
Norwegian Bokmål: 14 depottabletter - EU/1/07/395/071 - KLAR 28 depottabletter - EU/1/07/395/011 - KLAR 30 depottabletter - EU/1/07/395/012 - KLAR 49 depottabletter - EU/1/07/395/013 - KLAR 56 depottabletter - EU/1/07/395/014 - KLAR 98 depottabletter - EU/1/07/395/015 - KLAR
English: 14 prolonged-release tablets - EU/1/07/395/070 28 prolonged-release tablets - EU/1/07/395/045 49 prolonged-release tablets - EU/1/07/395/046 56 prolonged-release tablets - EU/1/07/395/047 98 prolonged-release tablets - EU/1/07/395/048
Norwegian Bokmål: 14 depottabletter - EU/1/07/395/070 28 depottabletter - EU/1/07/395/045 49 depottabletter - EU/1/07/395/046 56 depottabletter - EU/1/07/395/047 98 depottabletter - EU/1/07/395/048
English: Mon, Tue, Wed, Thu, Fri, Sat, Sun
Norwegian Bokmål: Ma., Ti., On., To., Fr., Lø., Sø.
English: vomiting, nausea,
Norwegian Bokmål: • kløe, utslett
English: DATE OF REVISION OF THE TEXT
Norwegian Bokmål: Responderanalyse
English: 14 prolonged-release tablets - EU/1/07/395/075 - WHITE 28 prolonged-release tablets - EU/1/07/395/036 - WHITE 30 prolonged-release tablets - EU/1/07/395/037 - WHITE 49 prolonged-release tablets - EU/1/07/395/038 - WHITE 56 prolonged-release tablets - EU/1/07/395/039 - WHITE 98 prolonged-release tablets - EU/1/07/395/040 - WHITE
Norwegian Bokmål: 14 depottabletter - EU/1/07/395/075 - HVIT 28 depottabletter - EU/1/07/395/036 - HVIT 30 depottabletter - EU/1/07/395/037 - HVIT 49 depottabletter - EU/1/07/395/038 - HVIT 56 depottabletter - EU/1/07/395/039 - HVIT 98 depottabletter - EU/1/07/395/040 - HVIT
English: 14 prolonged-release tablets - EU/1/07/395/065 - CLEAR 28 prolonged-release tablets - EU/1/07/395/001 - CLEAR 30 prolonged-release tablets - EU/1/07/395/002 - CLEAR 49 prolonged-release tablets - EU/1/07/395/003 - CLEAR 56 prolonged-release tablets - EU/1/07/395/004 - CLEAR 98 prolonged-release tablets - EU/1/07/395/005 - CLEAR
Norwegian Bokmål: 14 depottabletter - EU/1/07/395/065 - KLAR 28 depottabletter - EU/1/07/395/001 - KLAR 30 depottabletter - EU/1/07/395/002 - KLAR 49 depottabletter - EU/1/07/395/003 - KLAR 56 depottabletter - EU/1/07/395/004 - KLAR 98 depottabletter - EU/1/07/395/005 - KLAR
English: 14 prolonged-release tablets - EU/1/07/395/076 28 prolonged-release tablets - EU/1/07/395/053 49 prolonged-release tablets - EU/1/07/395/054 56 prolonged-release tablets - EU/1/07/395/055 98 prolonged-release tablets - EU/1/07/395/056
Norwegian Bokmål: 14 depottabletter - EU/1/07/395/076 28 depottabletter - EU/1/07/395/053 49 depottabletter - EU/1/07/395/054 56 depottabletter - EU/1/07/395/055 98 depottabletter - EU/1/07/395/056
English: 14 prolonged-release tablets - EU/1/07/395/066 - WHITE 28 prolonged-release tablets - EU/1/07/395/021 - WHITE 30 prolonged-release tablets - EU/1/07/395/022 - WHITE 49 prolonged-release tablets - EU/1/07/395/023 - WHITE 56 prolonged-release tablets - EU/1/07/395/024 - WHITE 98 prolonged-release tablets - EU/1/07/395/025 - WHITE
Norwegian Bokmål: 14 depottabletter - EU/1/07/395/066 - HVIT 28 depottabletter - EU/1/07/395/021 - HVIT 30 depottabletter - EU/1/07/395/022 - HVIT 49 depottabletter - EU/1/07/395/023 - HVIT 56 depottabletter - EU/1/07/395/024 - HVIT 98 depottabletter - EU/1/07/395/025 - HVIT
English: 14 prolonged-release tablets - EU/1/07/395/067 28 prolonged-release tablets - EU/1/07/395/041 49 prolonged-release tablets - EU/1/07/395/042 56 prolonged-release tablets - EU/1/07/395/043 98 prolonged-release tablets - EU/1/07/395/044
Norwegian Bokmål: 14 depottabletter - EU/1/07/395/067 28 depottabletter - EU/1/07/395/041 49 depottabletter - EU/1/07/395/042 56 depottabletter - EU/1/07/395/043 98 depottabletter - EU/1/07/395/044
English: 14 prolonged-release tablets - EU/1/07/395/073 28 prolonged-release tablets - EU/1/07/395/049 49 prolonged-release tablets - EU/1/07/395/050 56 prolonged-release tablets - EU/1/07/395/051 98 prolonged-release tablets - EU/1/07/395/052
Norwegian Bokmål: 14 depottabletter - EU/1/07/395/073 28 depottabletter - EU/1/07/395/049 49 depottabletter - EU/1/07/395/050 56 depottabletter - EU/1/07/395/051 98 depottabletter - EU/1/07/395/052